Med-Chemist : "Quintessential Medicinal Chemistry"
Wednesday, February 14, 2024
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
›
In continuation of my update on aripiprazole Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announced ...
Tuesday, February 13, 2024
FDA Approves Uzedy (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
›
In continuation of my update on Uzedy (risperidone) Teva Pharmaceuticals, announced the U.S. Food and Drug Administration (FDA) approval...
Wednesday, February 7, 2024
FDA Grants Accelerated Approval to Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy
›
Travere Therapeutics, Inc. (Nasdaq: TVTX) announced the U.S. Food and Drug Administration (FDA) approval to Filspari ™ (sparsentan) to re...
Saturday, February 3, 2024
FDA Approves Veozah (fezolinetant) for the Treatment of Vasomotor Symptoms Due to Menopause
›
Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approval of Veozah (fezolinetant) 45 mg once daily for the tr...
Thursday, January 25, 2024
FDA Approves RizaFilm (rizatriptan) Oral Film for the Treatment of Acute Migraine
›
In continuation of my update on rizatriptan IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT), announced the U.S. Food and Drug Administration approv...
Saturday, January 6, 2024
FDA Approves Joenja (leniolisib) for the Treatment of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)
›
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announced the USFDA approval...
Monday, January 23, 2023
FDA Approves Iyuzeh (latanoprost ophthalmic solution) for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
›
In continuation of my update on Latanoprost Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical...
Friday, January 20, 2023
FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
›
Rigel Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Rezlidhia (olutasidenib) capsules for the t...
Thursday, January 19, 2023
FDA Approves Krazati (adagrasib) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
›
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, announced the U.S. Food and Drug Administration (FDA) approval of ...
Wednesday, January 18, 2023
FDA Approves Olpruva (sodium phenylbutyrate) for Patients with Urea Cycle Disorders
›
In continuation of my update on Phenyl butyrate Acer Therapeutics Inc. and its collaboration partner, RELIEF THERAPEUTICS Holding SA (“Rel...
Tuesday, January 17, 2023
FDA Approves Sezaby (phenobarbital sodium powder for injection) for the Treatment of Neonatal Seizures
›
In continuation of my update on Phenobarbitol Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Ltd. announce...
Monday, January 16, 2023
FDA Approves Airsupra (albuterol/budesonide) Metered-Dose Inhaler to Reduce the Risk of Asthma Exacerbations
›
In continuation of my update on albuterol / budesonide Salbutamol ,/ albuterol Budesonide// Pulmicort Airsupra (albuterol/budesonide), form...
Friday, January 13, 2023
FDA Approves Sunlenca (lenacapavir) Twice-Yearly Treatment for People Living With Multi-Drug Resistant HIV
›
Gilead Sciences, Inc. (Nasdaq: GILD) announced that Sunlenca ® (lenacapavir), in combination with other antiretroviral(s) (ARV), has bee...
‹
›
Home
View web version